ATG3

Across TCGA pan-cancer cohorts, ATG3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG3 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ATG3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

COAD, CCRCC, and HNSC are the cancer types where ATG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.911	1.000	.012	18	view →
CCRCC	OS	Median	III,IV	0.801	0.962	.032	3	view →
HNSC	DFS	Quartile	All	0.922	1.000	.033	3	view →
PDAC	OS	Tertile	All	0.628	0.958	.027	1	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG3–COAD (DFS)

Open the COAD breakdown →